KCNT1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2716401	0.53	20/20
SCHEMBL1842642	0.37	9/20
SCHEMBL1844278	0.37	9/20
SCHEMBL951323	0.44	7/20
SCHEMBL17732	0.43	7/20
SCHEMBL3115663	0.60	6/20
SCHEMBL3485740	0.55	5/20
SCHEMBL142101	0.49	5/20
SCHEMBL95851	0.51	4/20
SCHEMBL2215374	0.46	4/20
SCHEMBL1123080	0.45	4/20
SCHEMBL17920	0.43	4/20
SCHEMBL95850	0.52	3/20
SCHEMBL2320643	0.47	3/20
SCHEMBL1123075	0.45	3/20
SCHEMBL1123076	0.45	3/20
SCHEMBL1714383	0.43	3/20
SCHEMBL2520214	0.41	3/20
SCHEMBL2212938	0.37	3/20
SCHEMBL3101227	0.58	2/20

Clinical trials — most relevant to KCNT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery	PHASE4	RECRUITING
Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes	PHASE4	COMPLETED
Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users	PHASE4	UNKNOWN
Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR)	PHASE4	UNKNOWN
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric Participants With KCNT1-related Epilepsy	PHASE2	RECRUITING
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
Sandostatine® LP and Hyperinsulinism	PHASE2	COMPLETED
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK	PHASE1	COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epilepsy	nan	COMPLETED
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia	nan	UNKNOWN
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats	nan	COMPLETED
Gene Study for Infantile Onset Diabetes	nan	UNKNOWN
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats	nan	COMPLETED
Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias	nan	RECRUITING
Na+ Channel mRNA Regulation in Heart Failure	nan	COMPLETED
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED
Characteristics of Episodic Ataxia Syndrome	nan	COMPLETED
Interaction of Potassium and Genetic Risk Variants on Diabetes Risk	nan	COMPLETED
Genetic Study for Infantile Onset Diabetes Mellitus	nan	UNKNOWN
Building of a Diagnostic/Prognostic Database for Human ERG Variant Effects	nan	RECRUITING
Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients	nan	UNKNOWN
Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a KCNT1 binder may also engage these)

Protein	Name	Similarity
Q9Z258	—	1.000	Q9Z258 →
Q6ZPR4	—	1.000	Q6ZPR4 →
Q8QFV0	—	0.999	Q8QFV0 →
KCNT2	Potassium channel subfamily T member 2	0.989	landscape →
D3Z649	—	0.985	D3Z649 →
Q6UVM4	—	0.982	Q6UVM4 →
Q7RTP6	—	0.953	Q7RTP6 →
Q9JIB4	—	0.948	Q9JIB4 →
G3MWR8	—	0.948	G3MWR8 →
Q8CJ19	—	0.948	Q8CJ19 →
D3Z7P3	—	0.948	D3Z7P3 →
GLS	Glutaminase kidney isoform, mitochondrial	0.947	landscape →
Q2TBV5	—	0.944	Q2TBV5 →
Q4W5Z4	—	0.944	Q4W5Z4 →
A0JN27	—	0.944	A0JN27 →
Q13888	—	0.943	Q13888 →
Q6P1K8	—	0.942	Q6P1K8 →
P13264	—	0.941	P13264 →
Q8BWB6	—	0.939	Q8BWB6 →
Q62956	—	0.938	Q62956 →
ERBB4	Receptor tyrosine-protein kinase erbB-4	0.938	landscape →
Q4R8V4	—	0.937	Q4R8V4 →
Q9HB90	—	0.936	Q9HB90 →
A6QLE6	—	0.936	A6QLE6 →
Q99K70	—	0.936	Q99K70 →
Q2HJ19	—	0.936	Q2HJ19 →
P20651	—	0.936	P20651 →
P48453	—	0.935	P48453 →
A0A2R8RWN9	—	0.935	A0A2R8RWN9 →
PPP3CB	Serine/threonine protein phosphatase PP2B-alpha catalytic subunit	0.934	landscape →